The role of Bromelain and Liposomal Vitamin C in the treatment of chronic venous disease

source extracted confidence: high 2026-04-09
#humans #ascorbic-acid #bromelains #chronic-disease #treatment-outcome

The role of Bromelain and Liposomal Vitamin C in the treatment of chronic venous disease

Buso et al., 2025 | Vasa | Systematic Review

Citation

Buso Giacomo, Santini Paolo, ... Martini Romeo. The role of Bromelain and Liposomal Vitamin C in the treatment of chronic venous disease. Vasa. 2025-May;54(3):164-176. doi:10.1024/0301-1526/a001184

Abstract

Chronic venous disease (CVD) is a prevalent condition leading to significant morbidity and affecting quality of life. Among conservative treatment strategies, venoactive drugs are often recommended by major guidelines for the management of CVD. Bromelain and vitamin C are now emerging as promising options in the management of several chronic diseases owing to their anti-inflammatory, immunoregulatory, and antioxidant properties, though evidence remains scarce in this setting. This systematic review of the literature, endorsed by the Italian Society of Angiology and Vascular Medicine (Societa Italiana di Angiologia e Patologia Vascolare, SIAPAV), aims to evaluate the efficacy and safety of these compounds in the treatment of CVD. A comprehensive search yielded nine studies, two on bromelain and seven on vitamin C. No studies have evaluated the effects of bromelain and vitamin C alone or in combination, whereas both molecules were administered in combination with other nutritional supplements. Overall, CVD-related symptoms and edema seem to improve with dietary supplement containing these two compounds, with no major safety issues reported. Bromelain and vitamin C may thus represent attractive options in the management of patients with symptomatic CVD and/or presence of venous edema, provided optimal conservative treatment is in place. Dedicated clinical studies are needed to clarify the efficacy and safety of a combination of these molecules in CVD management.

Key Findings

Dedicated clinical studies are needed to clarify the efficacy and safety of a combination of these molecules in CVD management.

Outcomes Measured

  • inflammatory markers

Population

Field Value
Population symptomatic cvd and
Sample Size See abstract
Age Range See abstract
Condition See abstract

MeSH Terms

  • Humans
  • Ascorbic Acid
  • Bromelains
  • Chronic Disease
  • Treatment Outcome
  • Antioxidants
  • Liposomes
  • Venous Insufficiency

Evidence Classification

  • Level: Systematic Review
  • Publication Types: Journal Article, Systematic Review
  • Vertical: vitamin-c

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09